北京北陸藥業(yè)股份有限公司_CPHI制藥在線(xiàn)專(zhuān)業(yè)網(wǎng)上貿易平臺

北京北陸藥業(yè)股份有限公司

成立年份：1992

總資產(chǎn)（USD）：

員工總人數：500以上

主要競爭優(yōu)勢：

業(yè)務(wù)類(lèi)型：

年銷(xiāo)售額（USD）：

主要銷(xiāo)售市場(chǎng)：

業(yè)務(wù)類(lèi)型：

主要產(chǎn)品類(lèi)別：

所有產(chǎn)品：

簡(jiǎn)介

Founded in 1992, Beilu is mainly engaged in the research & development, production and sales of pharmaceutical products. It is high-tech innovation company with core competence in the Contrast Media domestic. It has around 650 employees with 0.82 Bn/￥ revenue in 2019. Beilu provides complete Contrast Media products suitable for X-Ray and Magnetic Resonance Imaging (MRI), and it is the leading manufacturer in the Contrast Media field in China. It is one of the 1st batches of listed enterprises in GEM of SZSE (Ticker: 300016.SZ) in China.

Beilu's main products are Contrast Media, Anti-anxiety traditional Chinese medicine, and Anti-diabetic drugs to benefit people and improve their quality of life. Contrast Media are widely used to improve pictures of the inside of the body produced by X-rays, computed tomography (CT), magnetic resonance (MR) imaging, etc. Anti-anxiety traditional Chinese medicine is the original product with Chinese patent to contribute to improving the physical and mental status. And Anti-diabetic drugs are hypoglycemic drugs for the treatment of type 2 diabetes.

相關(guān)企業(yè)

蘇州海景醫藥科技有限公司

北京北陸藥業(yè)股份有限公司相關(guān)資訊

一周藥聞復盤(pán)|CPHI制藥在線(xiàn)（2025.3.24-3.28）

出于人為因素的績(jì)效管理，終將流于形式

被“追債”16億！這家Biotech陷入僵局

國控VS華潤，千億藥商最新業(yè)績(jì)發(fā)布（附圖表）

中國澳門(mén)藥物監督管理局批準馴鹿生物CAR-T產(chǎn)品伊基奧侖賽注射液上市

世界首款治療早期阿爾茨海默病的藥物樂(lè )意保?榮獲日本第12屆技術(shù)管理與創(chuàng )新獎首相獎

北京北陸藥業(yè)股份有限公司共有15個(gè)產(chǎn)品

CAS:67-43-6, Diethylenetriaminepentaacetic acid (DTPA)

CAS號：67-43-6

簡(jiǎn)介：CAS No.: 67-43-6 Molecular formula: C??H??N?O?? Molecular weight: 393.35 Quality standard: CP Characteristics: White powder Content (HPLC): ≥99.0% Packing: 2.5KG/ drum Storage: Protected from light, sealed tightly

CAS No.: 35453-19-1Iopamidol Intermediate (order based) 5-Amino-2,4,6-triiodoisophthalic acid

CAS號：35453-19-1

簡(jiǎn)介：CAS No.: 35453-19-1 Molecular formula: C8H4I3NO4 Molecular weight: 558.84 Quality standard: CP, USP Content (HPLC): ≥99.0% Packing: 25KG, 50KG/drum Storage: Protected from light, sealed tightly

Gadopentetate Dimeglumine

CAS號：86050-77-3

簡(jiǎn)介：CAS No.: 86050-77-3 Molecular formula: C28H54GdN5O20·2 C7H17NO5 Molecular weight: 938 Quality standard: CP, USP Characteristics: White to light yellow powder, odorless Content (HPLC): ≥99.0% Packing: 25KG/ drum Storage

iopromide

CAS號：73334-07-3

簡(jiǎn)介： subject standard character White or yellowish powder with moisture absorption acidity 5.2～6.5 moisture ≤1.5% Heavy me

iopamidol

CAS號：62883-00-5

簡(jiǎn)介： subject standard character White or quasi-white powder

ioversol

CAS號：87771-40-2

簡(jiǎn)介： subject standard character White or almost white powder with moisture absorption acidity Ph=5.0～7.0 moisture ≤5.0% He

Iodixanol injection

CAS號：92339-11-2

簡(jiǎn)介：【 Introduction 】 Iodexanol injection is a non-ionic dimer iodine contrast agent and is an isotonic iodine contrast agent. It has been officially listed in the Drug Catalogue of National Basic Medical Insurance, Industrial and Commercial Insurance and Mate

Iopamidol injection

CAS號：60166-93-0

簡(jiǎn)介：Iopamidol Injection is the second-generation non-ionic iodinated Contrast Media

Gadopentetate Dimeglumine Injection

簡(jiǎn)介：Since Gadopentetate Dimeglumine Injection was launched in 1992 by Beilu Pharma in China, it was highly recommended and accepted by the radiologist, and quickly occupied the market with its excellent quality and reasonable price. Up to now, it has been saf

Iohexol Injection

簡(jiǎn)介：Iohexol Injection is a non-ionic Contrast Media. Compared with a traditional ionic Contrast Media, Iohexol Injection has the excellent molecular structure, it has greatly improved safety and significantly reduced adverse reactions, also it has excellent c

Iohexol

CAS號：76801-93-9

簡(jiǎn)介：Sub-type :C19H26I3N3O9 Sub-type: 821.14 Cas No.:66108-95-0 Quality standard :YBH00512009 Type: white or light brown powder Water content: 1.5% (HPLC): 99.0% Package :25kg 50kg/ barrel Storage: shading sealed storage

Ammonium ferric citrate effervescent granules (Furui Ming ?) -- iron contrast agent for oral magneti

CAS號：--

簡(jiǎn)介：Introduction: the product was first developed in China by Beiriku Pharmaceutical Co., Ltd. It is used in magnetic resonance abdominal examination. It is a double relative contrast agent: positive contrast agent in T1 examination and negative contrast agen

Glimepiride Tablets (Dibei ?)

CAS號：--

簡(jiǎn)介：Introduction: in September 2001, the domestic glimepiide tablet dibei was approved by the state drug administration and it belongs to the second class new drug in the country, and began to be sold in the domestic market in November.It has been well receiv

Jiuwei zhenxin Granules

CAS號：--

簡(jiǎn)介：Introduction: Jiuwei Zhenxin Granules is a domestic, is also a State Food and Drug Administration approved by the treatment of anxiety pure traditional Chinese medicine preparation.Its formula is unique, the application of new technology such as volatile

Repaglinide tablet

CAS號：--

簡(jiǎn)介：Introduction: Repaglinide is a non-sulfonylurea insulin secretory agent, and is one of the "five golden flowers" of oral hypoglycemic drugs. It is characterized by quick action, short action time, and belongs to the ultra-short action, so it is

CPHI制藥在線(xiàn)為您找到了北京北陸藥業(yè)股份有限公司共15 個(gè)產(chǎn)品，并有北京北陸藥業(yè)股份有限公司地址、北京北陸藥業(yè)股份有限公司電話(huà)、北京北陸藥業(yè)股份有限公司聯(lián)系人等信息，想要了解北京北陸藥業(yè)股份有限公司詳情盡在CPHI制藥在線(xiàn)。

推薦供應商